Actively Recruiting
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia
Led by University Hospital, Essen · Updated on 2024-12-06
100
Participants Needed
1
Research Sites
320 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with hereditary hemorrhagic telangiectasia (HHT) suffer from an inherited disorder leading to systemic vascular malformations. Mutations in several genes of the transforming growth factor (TGF)-β superfamily pathway influence angiogenesis in patients with HHT. The genetic loss of ALK1 or ENG alone are not sufficient to induce AVMs; environmental insults that could trigger angiogenesis (e.g. wounding) are also needed. In this study it will be analyzed if hypoxic induced factors could have an influence on the disease HHT.
CONDITIONS
Official Title
Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hereditary hemorrhagic telangiectasia (HHT) by genetic testing or meeting at least 3 Curacao Criteria
- Older than 17 years
- Able to provide informed consent
You will not qualify if you...
- Does not meet the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Essen
Essen, North Rhine-Westphalia, Germany, 45147
Actively Recruiting
Research Team
F
Freya Droege, MD
CONTACT
A
Anna Wrobeln, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here